基本信息
浏览量:60
职业迁徙
个人简介
We aim to translate our knowledge acquired through fundamental research into the clinical practice through development of novel diagnostic tests and the use of recent high-throughput genomic technologies including next generation sequencing and by innovative drug design strategies.
A major research interest of our group is to understand the implication of complement in human pathologies, with a particular accent on the link between complement dysregulation and overactivation with the development of kidney diseases. The major achievements related to kidney diseases are: the first discovery of Factor I (J. Med. Genet), C3 (Blood) and DGKe (Nature Genetics) genetic abnormalities as well as anti-Factor H antibodies (JASN) in aHUS; the clinical description of one of the largest C3 Glomerulopathy cohort and the first description of a pathogenic antibody, stabilizing the C5 convertase C5NeF (Kidney Int). We reported the largest cohort worldwide of genetic abnormalities identify in patients with complement deficiency (Frontiers of immunology). The clinical and basic research activities resulted in more than 100 papers published within the last 10 years. Presently, my group are studying 1) auto-antibodies directed against complement proteins in C3 Glomerulopathy. We aim to Identified the mechanisms leading to generation of auto-antibodies against complement proteins in C3G as well as characterization of their functional consequences and disease relevance. 2) the mechanisms of C3G, related to monoclonal gammopathies (a pre-cancerous condition) of renal significance. In an available cohort, we will characterize the physicochemical and binding properties, which make monoclonal immunoglobulins complement-activating entities and how this induces renal damage.3) the genetic susceptibility for the severe meningococcal infections and screening diagnostic tools for following complement activation during the disease. Our work will lead to novel strategies for treatment of severe meningococcal infections and may open new avenues for fighting infections caused by multidrug-resistant neisserial or streptococcal strains.
A major research interest of our group is to understand the implication of complement in human pathologies, with a particular accent on the link between complement dysregulation and overactivation with the development of kidney diseases. The major achievements related to kidney diseases are: the first discovery of Factor I (J. Med. Genet), C3 (Blood) and DGKe (Nature Genetics) genetic abnormalities as well as anti-Factor H antibodies (JASN) in aHUS; the clinical description of one of the largest C3 Glomerulopathy cohort and the first description of a pathogenic antibody, stabilizing the C5 convertase C5NeF (Kidney Int). We reported the largest cohort worldwide of genetic abnormalities identify in patients with complement deficiency (Frontiers of immunology). The clinical and basic research activities resulted in more than 100 papers published within the last 10 years. Presently, my group are studying 1) auto-antibodies directed against complement proteins in C3 Glomerulopathy. We aim to Identified the mechanisms leading to generation of auto-antibodies against complement proteins in C3G as well as characterization of their functional consequences and disease relevance. 2) the mechanisms of C3G, related to monoclonal gammopathies (a pre-cancerous condition) of renal significance. In an available cohort, we will characterize the physicochemical and binding properties, which make monoclonal immunoglobulins complement-activating entities and how this induces renal damage.3) the genetic susceptibility for the severe meningococcal infections and screening diagnostic tools for following complement activation during the disease. Our work will lead to novel strategies for treatment of severe meningococcal infections and may open new avenues for fighting infections caused by multidrug-resistant neisserial or streptococcal strains.
研究兴趣
论文共 298 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinica Chimica Actapp.117750, (2024)
引用0浏览0引用
0
0
Kathleen Dessaix, Christophe Bontoux,Olivier Aubert,Anne Grünenwald, Rebecca Sberro Soussan,Julien Zuber,Jean-Paul Duong Van Huyen,Dany Anglicheau,Christophe Legendre,Veronique Fremeaux Bacchi,Marion Rabant
American Journal of Transplantation (2024)
Journal of the American Society of Nephrology : JASN (2024)
Alistair Baber,Paul Legendre,Sophie Chauvet,Alexandre Karras,Samuel Deshayes,Antoine Huart,Marguerite Vignon, Kathleen Dessaix,Baptiste Hervier, Bruno Legallicier,Nicolas Martin Silva,Veronique Fremeaux-Bacchi,
KIDNEY INTERNATIONAL REPORTSno. 3 (2024): 712-716
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Associationno. 12 (2023): 2685-2693
Arnaud Garnier,Karine Brochard,Theresa Kwon, Anne-Laure Sellier-Leclercq,Annie Lahoche,Emma Allain Launay,François Nobili,Mathilde Caillez,Sophie Taque,Jerôme Harambat, Guylhene Michel-Bourdat,Vincent Guigonis,
引用7浏览0WOS引用
7
0
Anna Duval,Nicolas Maillard,Sophie Limou,Christophe Mariat, Sophie Ohlmann,Veronique Fremeaux Bacchi
Nephrology Dialysis Transplantationno. Supplement_1 (2023)
Etienne Jacotot,Laura Talamini, Srinivsasa Reddy Bonam,Angelica Thomaz Vieira,Véronique Fremeaux-Bacchi,Marko Radic,Marie-Agnès Dragon-Durey,Jose Manuel Lozano, Rafael Simone Saia,Sylviane Muller
Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccinationpp.63-128, (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn